Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine.

Peter L Greenberg, MD, Guillermo Garcia-Manero, MD, Michael R Moore, MD, Lloyd E. Damon, MD, Gail J. Roboz, MD, Helen Wei, Hagop Kantarjian, MD, Janet L. Franklin, MD, MPH

Blood (2009) 114 (22): 1769.

https://doi.org/10.1182/blood.V114.22.1769.1769

Published: 2009

Journal Articles

Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.

Roger M Lyons, Richard A. Larson, MD, Michael A. Kosmo, MD, Sunil Gandhi, Delong Liu, MD, PhD, Marc Chernoff, Luke Dreisbach, MD, Carmen Matei, Kuolong Hu, PhD, Janet L. Franklin, MD, MPH, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 1770.

https://doi.org/10.1182/blood.V114.22.1770.1770

Published: 2009

Journal Articles

An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS).

Pierre Fenaux, Hagop Kantarjian, MD, Roger Lyons, Richard A. Larson, MD, Mikkael A. Sekeres, MD, MS, Pamela S. Becker, MD, PhD, Petra Muus, MD, PhD, Kuolong Hu, PhD, Dietmar Berger, MD, PhD, Janet L. Franklin, MD, MPH

Blood (2009) 114 (22): 2765.

https://doi.org/10.1182/blood.V114.22.2765.2765

Published: 2009

Journal Articles

Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.

Jason N. Berman, MD, Robert B. Gerbing, PhD, Lillian Sung, MD, Kristen Miller, BS, Jessica A. Pollard, MD, Phoenix Ho, Derek Stirewalt, Jerald Radich, MD, Craig A. Hurwitz, MD, Nyla A. Heerema, PhD, Betsy Hirsch, MD, Susana C. Raimondi, PhD, Beverly Lange, MD, Alan S. Gamis, MD, Janet L. Franklin, MD, MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD, PhD

Blood (2009) 114 (22): 3115.

https://doi.org/10.1182/blood.V114.22.3115.3115

Published: 2009

Journal Articles

High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group.

Walter B. Walter, MD, PhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MS, Franklin O. Smith, MD, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Alan S. Gamis, MD, Janet L. Franklin, MD, MPH, Craig A. Hurwitz, MD, Michael R. Loken, PhD, Soheil Meshinchi, MD, PhD

Blood (2009) 114 (22): 1592.

https://doi.org/10.1182/blood.V114.22.1592.1592

Published: 2009

NARROW

Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine.

Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.

An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS).

Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.

High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group.

Email alerts

ASH Publications

American Society of Hematology

Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine.

Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.

An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS).

Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.

High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only